Artemis Medicare Reports Mixed Q4 Results: Profit Surges Despite EBITDA Decline

2 min read     Updated on 12 May 2025, 05:54 PM
scanxBy ScanX News Team
whatsapptwittershare
Overview

Artemis Medicare Services Ltd released its Q4 FY2024 financial results, showing a 6.22% increase in revenue to ₹239.00 crore and a 62.00% surge in net profit to ₹230.00 crore. However, EBITDA declined by 5.53% to ₹359.00 crore, with margin contracting to 14.96%. Annual performance was strong with revenue up 18.94% to ₹885.90 crore and net profit growing 29.21% to ₹49.10 crore.

8598308

*this image is generated using AI for illustrative purposes only.

Artemis Medicare Services , a prominent healthcare provider, has released its financial results for the fourth quarter of the fiscal year, revealing a mixed performance with notable growth in profit despite a decline in EBITDA.

Revenue Growth and Profit Surge

The company reported a consolidated revenue of ₹239.00 crore for Q4, marking a 6.22% increase from ₹225.00 crore in the same quarter of the previous year. This growth in revenue demonstrates the company's ability to expand its operations and attract more patients.

More impressively, Artemis Medicare's consolidated net profit saw a substantial rise, reaching ₹230.00 crore, up from ₹142.00 crore in the corresponding quarter of the previous year. This represents a remarkable 62.00% year-over-year increase in net profit, highlighting the company's improved profitability and operational efficiency.

EBITDA and Margin Contraction

Despite the strong revenue and profit growth, Artemis Medicare experienced a decline in its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). The EBITDA for Q4 stood at ₹359.00 crore, down from ₹380.00 crore in the same quarter last year, representing a 5.53% decrease.

Consequently, the EBITDA margin contracted to 14.96% from 16.85% in the year-ago period. This margin compression suggests that the company faced some challenges in managing its operational costs during the quarter.

Quarterly Performance Analysis

Looking at the quarterly trend, Artemis Medicare showed some fluctuations in its performance:

Metric (₹ in crore) Q4 FY2024 Q3 FY2024 QoQ Change
Revenue 241.20 248.90 -3.09%
EBITDA 46.30 49.70 -6.84%
Net Profit 20.60 22.10 -6.79%
EPS (₹) 1.32 1.42 -7.04%

The quarter-on-quarter comparison reveals a slight decline across key financial metrics. However, it's important to note that the healthcare sector often experiences seasonal fluctuations, and a single quarter's performance may not reflect the overall trend.

Annual Performance Highlights

For the full fiscal year, Artemis Medicare demonstrated strong growth:

  • Annual revenue reached ₹885.90 crore, up 18.94% from the previous year's ₹744.80 crore.
  • EBITDA for the year stood at ₹140.10 crore, showing a significant increase of 38.30% year-over-year.
  • The company's net profit for the fiscal year was ₹49.10 crore, representing a 29.21% growth compared to the previous year.

Conclusion

Artemis Medicare's Q4 results present a nuanced picture of the company's performance. While the substantial increase in net profit and revenue growth are positive indicators, the decline in EBITDA and margin contraction suggest that the company may need to focus on cost management in the coming quarters. The overall annual performance, however, remains strong, indicating that Artemis Medicare continues to strengthen its position in the healthcare sector.

Historical Stock Returns for Artemis Medicare Services

1 Day5 Days1 Month6 Months1 Year5 Years
+2.22%-0.60%-5.78%-21.63%-9.05%+1,286.93%
Artemis Medicare Services
View in Depthredirect
like18
dislike
Explore Other Articles
Praxis Home Retail Announces Rights Issue Schedule for August 2025 2 hours ago
Alldigi Tech Reports 11.3% Revenue Growth and 17.3% EBITDA Growth in Q1 FY26 3 hours ago
Indus Infra Trust Reports Q1 Results: Distribution of Rs. 3.25 Per Unit Declared 3 hours ago
Premier Explosives Secures ₹22.36 Crore International Order for Rocket Motors 3 hours ago
Orchid Pharma Secures Global Rights to Enmetazobactam Through Strategic Asset Acquisitions 4 hours ago
239.80
+5.20
(+2.22%)